Disc Medicine, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Watertown, mass., april 01, 2024 (globe newswire) -- disc medicine, inc. (nasdaq:iron), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented topline data from aurora, a phase 2 study of bitopertin in patients with epp. treatment with bitopertin resulted in statistically significant reductions in ppix, the primary endpoint, and significant improvements in the rate of phototoxic reactions with pain and the patient global impression of change (pgic). on the key secondary endpoint of cumulative time in sunlight on days without pain, bitopertin patients had a positive response consistent with beacon results, but the endpoint did not meet statistical significance due to strong placebo performance.

Watertown, mass., march 21, 2024 (globe newswire) -- disc medicine, inc. (nasdaq:iron), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided an update on recent program and corporate developments.

Watertown, mass., march 06, 2024 (globe newswire) -- disc medicine, inc. (nasdaq:iron), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the leerink partners global biopharma conference 2024 on monday, march 11th at 10:40 am et.

Pamela stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches pamela stephenson is an accomplished industry executive with over 25 years of global commercial leadership experience and a track record of numerous successful launches

Shanghai , feb. 20, 2024 /prnewswire/ -- mabwell (688062.sh), an innovative biopharmaceutical company with entire industry chain, announced that fda has granted orphan drug designation (odd) to 9mw3011 (r&d code in the us: mwtx-003/disc-3405) for the treatment of patients with polycythemia vera (pv).  fda orphan drug designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the united states.

Disc Medicine's (IRON) shares lose after a phase II study of bitopertin in patients with erythropoietic protoporphyria does not achieve the key secondary endpoint.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

WATERTOWN, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., PhD., President and Chief Executive Officer, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10th at 2:15 pm PT / 5:15 pm ET.

The mean of analysts' price targets for Disc Medicine, Inc. (IRON) points to a 38.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

WATERTOWN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at the Stifel 2023 Healthcare Conference on Wednesday, November 15th at 11:30 am ET. Disc will also give presentations at the Jefferies London Healthcare Conference on Thursday, November 16th at 9:30 am GMT / 4:30 am ET and the Piper Sandler 35th Annual Healthcare Conference on Thursday, November 30th at 2:30 pm ET.

WATERTOWN, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at four upcoming investor conferences:

Disc Medicine, Inc. (IRON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Disc Medicine, Inc. (IRON) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Disc Medicine stock has shown outstanding growth since the company joined the Nasdaq in December last year, gaining nearly 250%. The company released data today from a Phase 2 study of lead candidate Bitopertin -acquired from Roche - in the rare disease Erythropoietic Porphyria. EPP patients suffer skin damaging skin conditions when exposed to sunlight - results from the BEACON study demonstrated marked and encouraging improvements.

Disc Medicine is a clinical-stage biopharmaceutical company specializing in treating blood disorders. The company's lead therapy, bitopertin, is in phase 2 trials to treat a rare inherited blood disorder.